Drawing for AMVIREX

USPTO serial 76070328

AMVIREX

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
Examiner
KIM, YONG OH
Law office
FILE REPOSITORY (FRANCONIA)

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with AMVIREX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005PHARMACEUTICAL PREPARATION WITH ANTIVIRAL AND/OR ANTIMICROBIAL PROPERTIES FOR USE IN THE TREATMENT OF VIRAL INFLUENZA (FLU), SHINGLES, HERPES (HERPES SIMPLEX VIRUS), VARICELLA-ZOSTER VIRUS (HERPES ZOSTER), GENICULATE ZOSTER, HERPES KERATITIS, CHICKEN POX, CYTOMEGALOVIRUS, EPSTEIN-BARR, PAPILLOMA VIRUS, VIRAL PARAINFLUENZA, ADENOVIRUS, VIRAL ENCEPHALITIS, VIRAL MENINGITIS, ARBOVIRUS, ARENAVIRUS, PICORNAVIRUS, CORONAVIRUS, SYNTIAL VIRUS, VIRAL INFECTIONS, COMMON COLDS CAUSED BY VIRUSES, HUMAN IMMUNODEFICIENCY VIRUS (HIV), GINGIVOSTOMATITIS, ROSEOLA INFANTUM, ORGAN TRANSPLANT REJECTION, PNEUMONIA, INFECTIOUS MONONUCLEOSIS, UVEITIS, RETINITIS, HUMAN PAPILLOMA VIRUS, CERVICAL CARCINOMA, VAGINAL CARCINOMA, VULVOVAGINITIS, HUMAN HERPES IV, ANF KAPOSI'S SARCOMAACTIVEFeb 19, 2002

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 23, 2003MAILPAPER RECEIVED
Dec 3, 2002ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 22, 2002CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 13, 2002DOCKASSIGNED TO EXAMINER
Mar 11, 2002SUPCSTATEMENT OF USE PROCESSING COMPLETE
Feb 27, 2002MAILPAPER RECEIVED
Feb 21, 2002IUAFUSE AMENDMENT FILED
Aug 21, 2001NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 29, 2001PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 16, 2001NPUBNOTICE OF PUBLICATION
Jan 15, 2001CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Jan 3, 2001CNEAEXAMINER'S AMENDMENT MAILED
Dec 28, 2000DOCKASSIGNED TO EXAMINER
Nov 8, 2000DOCKASSIGNED TO EXAMINER

Frequently asked questions

Related guidance